DOCSLIB.ORG

Medication Coverage Policy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Medication Coverage Policy MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Glaucoma P&T DATE: 2/15/2017 THERAPEUTIC CLASS Ophthalmic Disorders REVIEW HISTORY 11/15, 9/12 LOB AFFECTED Medi-Cal, SJHA (MONTH/YEAR) This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the HPSJ Pharmacy and Therapeutic Advisory Committee. OVERVIEW Treatment of open-angle glaucoma includes 3 options, alone or in combination: medical treatment, laser therapy, or incisional glaucoma surgery. Pharmacologic options are the most common initial intervention to reduce intraocular pressure and the choice of medication is typically determined by potential cost, side effects, and dosing schedules.1 Primary angle closure glaucoma usually requires surgery and acute management.2 The purpose of this Glaucoma Coverage Policy is to review the coverage criteria of HPSJ’s formulary glaucoma agents (Table 1). Table 1: Available Glaucoma Medications (Current as of 1/2017) Generic Name (Brand Fml Cost per Available Strengths Notes Name) Limits Rx* BETA-ADRENERGIC BLOCKERS 0.25 % eye drops, suspension - $295.79 Betaxolol Hcl (Betoptic S) 0.5 % eye drops - $43.66 Carteolol Hcl 1 % eye drops - $9.96 Levobunolol Hcl 0.5 % eye drops - $20.99 Metipranolol 0.3 % eye drops - $20.53 Timolol hemihydrate 0.5 % eye drops - $110.46 (Betimol) Timolol Maleate/Pf 0.25 % eye drops in a dropperette - $338.76 (Timoptic Ocudose (Pf)) 0.5 % eye drops in a dropperette - --- Non-Formulary: Alternatives are timolol Istalol: 0.5 % eye drops NF $142.47 maleate, betaxolol, carteolol, levobunolol, metipranol Timolol Maleate (Istalol, 0.25 % eye drops - $2.59 Timoptic) 0.5 % eye drops - $4.40 0.25 % eye gel forming solution - $93.59 0.5 % eye gel forming solution - $106.83 CARBONIC ANHYDRASE INHIBITORS 125 mg tablet - $45.40 Acetazolamide 250 mg tablet - $99.71 500 mg ER capsule - $108.50 Brinzolamide (Azopt) 1 % eye drops, suspension - $255.21 Dorzolamide Hcl 2 % eye drops - $30.45 25 mg tablet - $165.49 Methazolamide 50 mg tablet - $131.00 ALPHA-2 ADRENERGIC AGONISTS 0.1 % eye drops - $134.39 Brimonidine Tartrate 0.15% eye drops - $113.18 (Alphagan P) 0.2% eye drops - $15.66 Apraclonidine Hcl 0.5 % eye drops - $64.34 (Iopidine) 1 % eye drops in a dropperette - --- PROSTAGLANDIN ANALOGUES Bimatoprost (Lumigan) 0.01 % eye drops - $170.37 Latanoprost (Xalatan) 0.005 % eye drops - $ 8.50 Non-Formulary: Alternatives are Tafluprost (Zioptan) 0.0015 % eye drops NF $168.49 Lumigan, Latanoprost Non-Formulary: Alternatives are Travoprost (Travatan Z) 0.004 % eye drops NF $170.98 Lumigan, Latanoprost Travoprost Non-Formulary: Alternatives are 0.004 % eye drops NF $141.38 benzalkonium Lumigan, Latanoprost Coverage Policy – Ophthalmic Disorders – Glaucoma Page 1 Generic Name (Brand Fml Cost per Available Strengths Notes Name) Limits Rx* CHOLINERGIC AGONISTS/PARASYMPATHOMIMETIC DRUGS Carbachol (Miostat) 0.01 % intraocular solution - --- Echothiophate Iodide 0.125 % eye drops - $87.57 (Phospholine Iodide) 1 % eye drops - $67.45 Pilocarpine Hcl 2 % eye drops - $65.78 4 % eye drops - $76.09 COMBINATION AGENTS Brinzolamide/Brimonidine 1 %-0.2 % eye drops, suspension - $131.35 (Simbrinza) Non-Formulary: Alternative is Dorzolamide Hcl/Timolol 2 %-0.5 % eye drops NF $147.51 dorzolamide/timolol maleate or use as Maleate Pf (Cosopt Pf) separate agents Dorzolamide Hcl/Timolol 2 %-0.5 % eye drops - $46.97 Maleate (Cosopt) Brimonidine Tartrate/Timolol 0.2 %-0.5 % eye drops - $159.61 (Combigan) NF = Non-Formulary Bolded items = Brand name drug cost/utilization *Cost/Rx based on HPSJ utilization historical data from February 2016 through January 2017 EVALUATION CRITERIA FOR APPROVAL/EXCEPTION CONSIDERATION Below are the coverage criteria and required information for each agent. These coverage criteria have been reviewed & approved by the HPSJ Pharmacy & Therapeutics (P&T) Advisory Committee. For conditions not covered under this Coverage Policy, HPSJ will make the determination based on Medical Necessity as described in HSPJ Medical Review Guidelines (UM06). Beta-Adrenergic Blockers Betaxolol Hcl (Betoptic S), Carteolol Hcl, Levobunolol Hcl, Metipranolol, Timolol hemihydrate (Betimol), Timolol Maleate/Pf (Timoptic Ocudose (Pf)), Timolol Maleate (Istalol, Timoptic) Betaxolol Hcl (Betoptic S), Carteolol Hcl, Levobunolol Hcl, Metipranolol, Timolol hemihydrate (Betimol), Timolol Maleate/Pf (Timoptic Ocudose (Pf)), Timolol Maleate (Timoptic) Coverage Criteria: None Limits: None Required Information for Approval: N/A Other Notes: None Non-Formulary: Istalol Carbonic Anhydrase Inhibitors Acetazolamide, Brinzolamide (Azopt), Dorzolamide Hcl, Methazolamide Coverage Criteria: None Limits: None Required Information for Approval: N/A Other Notes: None Alpha-2 Adrenergic Agonists Brimonidine Tartrate (Alphagan P), Apraclonidine Hcl (Iopidine) Coverage Criteria: None Limits: None Required Information for Approval: N/A Other Notes: None Coverage Policy – Ophthalmic Disorders – Glaucoma Page 2 Prostaglandin Analogues Bimatoprost (Lumigan), Latanoprost (Xalatan), Tafluprost (Zioptan), Travoprost (Travatan Z), Travoprost benzalkonium Bimatoprost (Lumigan), Latanoprost (Xalatan) Coverage Criteria: None Limits: None Required Information for Approval: N/A Other Notes: None Non-Formulary: Tafluprost (Zioptan), Travoprost (Travatan Z), Travoprost benzalkonium Cholinergic Agonists/Parasympathomimetic Drugs Carbachol (Miostat), Echothiophate Iodide (Phospholine Iodide), Pilocarpine Hcl Coverage Criteria: None Limits: None Required Information for Approval: N/A Other Notes: None Combination Agents Brinzolamide/Brimonidine (Simbrinza), Dorzolamide Hcl/Timolol Maleate (Cosopt Pf), Brimonidine Tartrate/Timolol (Combigan) Dorzolamide Hcl/Timolol Maleate (Cosopt), Brimonidine Tartrate/Timolol (Combigan), Brinzolamide/Brimonidine (Simbrinza) Coverage Criteria: None Limits: None Required Information for Approval: N/A Other Notes: None Non-Formulary: Cosopt Pf CLINICAL JUSTIFICATION Primary angle-closure glaucoma is treated with iridotomy, using either a thermal or neodymium ytrium-aluminum- garnet (Nd:YAg) laser.1 Acute attacks can be treated with topical beta-blockers; topical alpha2-agonists; topical, oral, or intravenous carbonic anhydrase inhibitors; topical miotics; or oral or intravenous hyperosmotic agents, but medical therapy should be followed by iridotomy as soon as possible.1 Prostaglandin analog and beta-blocker eye drops are most commonly used as initial treatment for open-angle glaucoma. Prostaglandin analogs are the most effective at lowering IOP and are considered initial treatment while other agents may be added on. The American Academy of Ophthalmology recommends weighing effectiveness, side effects, and frequency of dosing when considering pharmacologic therapy because side effects and dosing frequency may affect adherence. If one drug fails, the ophthalmologist can replace the drug or may use combination therapy depending on whether the patient has responded to the first medication (the first medication should not be continued if there is no response in IOP lowering).2 Refractory glaucoma can be treated with laser therapy, surgery, or stents.2 Coverage Policy – Ophthalmic Disorders – Glaucoma Page 3 Table 2: Primary Open-Angle Glaucoma 20151 Coverage Policy – Ophthalmic Disorders – Glaucoma Page 4 REFERENCES 1. American Academy of Ophthalmology Glaucoma Panel. Preferred Practice Pattern® Guidelines. Primary Angle Closure. San Francisco, CA: American Academy of Ophthalmology; 2015. Available at: https://www.aao.org/preferred-practice- pattern/primary-angle-closure-ppp-2015. 2. American Academy of Ophthalmology Glaucoma Panel. Preferred Practice Pattern® Guidelines. Primary Open-Angle Glaucoma. San Francisco, CA: American Academy of Ophthalmology; 2015 Available at: https://www.aao.org/preferred- practice-pattern/primary-open-angle-glaucoma-ppp-2015. REVIEW & EDIT HISTORY Document Changes Reference Date P&T Chairman Creation of Policy Formulary Realignment 9-18-12.xlsx 9/12 Jonathan Szkotak, PharmD Update to Policy HPSJ Coverage Policy – Ophthalmic Disorders – 11/15 Johnathan Yeh, PharmD Glaucoma 2015-11.docx Update to Policy HPSJ Coverage Policy – Ophthalmic Disorders – 2/17 Johnathan Yeh, PharmD Glaucoma 2017-02.docx Note: All changes are approved by the HPSJ P&T Committee before incorporation into the utilization policy Coverage Policy – Ophthalmic Disorders – Glaucoma Page 5 .
Load more

Recommended publications
  • Intraocular Pressure Rise After Phacoemulsification Prophylactic
    British Journal of Ophthalmology 1995; 79: 809-813 809 Intraocular pressure rise after phacoemulsification Br J Ophthalmol: first published as 10.1136/bjo.79.9.809 on 1 September 1995. Downloaded from with posterior chamber lens implantation: effect of prophylactic medication, wound closure, and surgeon's experience Thomas G Bomer, Wolf-Dietrich A Lagreze, Jens Funk Abstract pressure rises usually occur between 6 and 8 Aims-A prospective clinical trial was hours after surgery.6 carried out to evaluate the effect of Various antiglaucomatous agents have been prophylactic medication, the technique of used to prevent the intraocular pressure rise wound closure, and the surgeon's experi- after cataract extraction. Oral acetazolamide15 16 ence on the intraocular pressure rise after and topical timolol'6-19 lowered the pressure cataract extraction. rise in the early period after intracapsular and Methods-In 100 eyes, the intraocular extracapsular cataract extraction. Levobunolol pressure was measured before as well as proved to be superior to timolol 4-7 hours 2-4, 5-7, and 22-24 hours after phaco- after extracapsular cataract extraction.20 Apra- emulsification and posterior chamber lens clonidine lowered the intraocular pressure rise implantation. Each of 25 patients received after uncomplicated phacoemulsification21 and either 1% topical apraclonidine, 0.5%/o extracapsular cataract extraction22 23 when topical levobunolol, 500 mg oral acetazo- given 30 minutes to 1 hour before surgery, lamide, or placebo. Forty four eyes were whereas immediate postoperative treatment operated with sclerocorneal sutureless with apraclonidine was ineffective.22 24 Miotics tunnel and 56 eyes with corneoscleral are frequently used to promote miosis and incision and suture.
    [Show full text]
  • Brimonidine Tartrate; Brinzolamide
    Contains Nonbinding Recommendations Draft Guidance on Brimonidine Tartrate ; Brinzolamide This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs. Active Ingredient: Brimonidine tartrate; Brinzolamide Dosage Form; Route: Suspension/drops; ophthalmic Strength: 0.2%; 1% Recommended Studies: One study Type of study: Bioequivalence (BE) study with clinical endpoint Design: Randomized (1:1), double-masked, parallel, two-arm, in vivo Strength: 0.2%; 1% Subjects: Males and females with chronic open angle glaucoma or ocular hypertension in both eyes. Additional comments: Specific recommendations are provided below. ______________________________________________________________________________ Analytes to measure (in appropriate biological fluid): Not applicable Bioequivalence based on (95% CI): Clinical endpoint Additional comments regarding the BE study with clinical endpoint: 1. The Office of Generic Drugs (OGD) recommends conducting a BE study with a clinical endpoint in the treatment of open angle glaucoma and ocular hypertension comparing the test product to the reference listed drug (RLD), each applied as one drop in both eyes three times daily at approximately 8:00 a.m., 4:00 p.m., and 10:00 p.m. for 42 days (6 weeks). 2. Inclusion criteria (the sponsor may add additional criteria): a. Male or nonpregnant females aged at least 18 years with chronic open angle glaucoma or ocular hypertension in both eyes b.
    [Show full text]
  • Table 1. Glaucoma Medications: Mechanisms, Dosing and Precautions Brand Generic Mechanism of Action Dosage/Avg
    OPTOMETRIC STUDY CENTER Table 1. Glaucoma Medications: Mechanisms, Dosing and Precautions Brand Generic Mechanism of Action Dosage/Avg. % Product Sizes Side Effects Warnings Reduction CHOLINERGIC AGENTS Direct Pilocarpine (generic) Pilocarpine 1%, 2%, 4% Increases trabecular outflow BID-QID/15-25% 15ml Headache, blurred vision, myopia, retinal detachment, bronchiole constriction, Angle closure, shortness of breath, retinal narrowing of angle detachment Indirect Phospholine Iodide (Pfizer) Echothiophate iodide 0.125% Increases trabecular outflow QD-BID/15-25% 5ml Same as above plus cataractogenic iris cysts in children, pupillary block, Same as above, plus avoid prior to any increased paralysis with succinylcholine general anesthetic procedure ALPHA-2 AGONISTS Alphagan P (Allergan) Brimonidine tartrate 0.1%, 0.15% with Purite Decreases aqueous production, increases BID-TID/up to 26% 5ml, 10ml, 15ml Dry mouth, hypotension, bradycardia, follicular conjunctivitis, ocular irritation, Monitor for shortness of breath, dizziness, preservative uveoscleral outflow pruritus, dermatitis, conjunctival blanching, eyelid retraction, mydriasis, drug ocular redness and itching, fatigue allergy Brimonidine tartrate Brimonidine tartrate 0.15%, 0.2% Same as above Same as above 5ml, 10ml Same as above Same as above (generic) Iopidine (Novartis) Apraclonidine 0.5% Decreases aqueous production BID-TID/up to 25% 5ml, 10ml Same as above but higher drug allergy (40%) Same as above BETA-BLOCKERS Non-selective Betagan (Allergan) Levobunolol 0.25%, 0.5% Decreases
    [Show full text]
  • NEW ZEALAND DATA SHEET 1. PRODUCT NAME IOPIDINE® (Apraclonidine Hydrochloride) Eye Drops 0.5%
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME IOPIDINE® (apraclonidine hydrochloride) Eye Drops 0.5%. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of Iopidine Eye Drops 0.5% contains apraclonidine hydrochloride 5.75 mg, equivalent to apraclonidine base 5 mg. Excipient with known effect Benzalkonium chloride 0.1 mg per 1 mL as a preservative. For the full list of excipients, see section 6.1. 2. PHARMACEUTICAL FORM Eye drops, solution, sterile, isotonic. 4. CLINICAL PARTICULARS 4.1. Therapeutic indications Iopidine Eye Drops 0.5% are indicated for short-term adjunctive therapy in patients on maximally tolerated medical therapy who require additional IOP reduction. Patients on maximally tolerated medical therapy who are treated with Iopidine Eye Drops 0.5% to delay surgery should have frequent follow up examinations and treatment should be discontinued if the intraocular pressure rises significantly. The addition of Iopidine Eye Drops 0.5% to patients already using two aqueous suppressing drugs (i.e. beta-blocker plus carbonic anhydrase inhibitor) as part of their maximally tolerated medical therapy may not provide additional benefit. This is because apraclonidine is an aqueous-suppressing drug and the addition of a third aqueous suppressant may not significantly reduce IOP. The IOP-lowering efficacy of Iopidine Eye Drops 0.5% diminishes over time in some patients. This loss of effect, or tachyphylaxis, appears to be an individual occurrence with a variable time of onset and should be closely monitored. The benefit for most patients is less than one month. 4.2. Dose and method of administration Dose One drop of Iopidine Eye Drops 0.5% should be instilled into the affected eye(s) three times per day.
    [Show full text]
  • ALPHAGAN® 0.2% Safely and Effectively
    NDA 20613/S-031 Page 4 HIGHLIGHTS OF PRESCRIBING INFORMATION ___________ ___________ ADVERSE REACTIONS Most common adverse reactions occurring in These highlights do not include all the information needed approximately 10 to 30% of patients receiving brimonidine to use ALPHAGAN® 0.2% safely and effectively. See full ophthalmic solution 0.2% included oral dryness, ocular prescribing information for ALPHAGAN® 0.2%. hyperemia, burning and stinging, headache, blurring, foreign body sensation, fatigue/drowsiness, conjunctival ALPHAGAN® (brimonidine tartrate ophthalmic solution) follicles, ocular allergic reactions, and ocular pruritus. (6.1) 0.2% For Topical Ophthalmic Use To report SUSPECTED ADVERSE REACTIONS, Initial U.S. Approval: 1996 contact Allergan at 1-800-433-8871 or the FDA at 1­ 800-FDA-1088 or www.fda.gov/medwatch. _________ _________ INDICATIONS AND USAGE ___________ ____________ DRUG INTERACTIONS ALPHAGAN® 0.2% is an alpha adrenergic agonist indicated Antihypertensives/cardiac glycosides may lower blood for lowering intraocular pressure (IOP) in patients with open- pressure. (7.1) angle glaucoma or ocular hypertension. (1) ________ ________ Use with CNS depressants may result in an additive or DOSAGE AND ADMINISTRATION potentiating effect. (7.2) One drop in the affected eye(s), three times daily, Tricyclic antidepressants may potentially blunt the approximately 8 hours apart. (2) hypotensive effect of systemic clonidine. (7.3) _______ _______ DOSAGE FORMS AND STRENGTHS Monoamine oxidase inhibitors may result in increased Solution containing 2 mg/mL brimonidine tartrate. (3) hypotension. (7.4) _________ _____________ _______ ______ CONTRAINDICATIONS USE IN SPECIFIC POPULATIONS Neonates and infants (under the age of 2 years). (4.1) Use with caution in children > 2 years of age.
    [Show full text]
  • New Medicines Committee Briefing March 2015 Simbrinza
    New Medicines Committee Briefing March 2015 Simbrinza® (Brinzolamide 10mg + Brimonidine tartrate 2mg/ml) for treatment of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension. Simbrinza® is to be reviewed for use within: Primary Care Secondary Care Summary: Simbrinza® is a combination of brinzolamide which is a carbonic anhydrase (CA-II) inhibitor and brimonidine which is an alpha-2 adrenergic agonist. Simbrinza® is licensed for the treatment of elevated IOP in adult patients with open-angle glaucoma or ocular hypertension whom failed on mono-therapy. Simbrinza® is administered twice daily in the affected eye(s). Simbrinza® is the first combination therapy which does not contain a beta-blocker. SMC has accepted Simbrinza® for use within NHS Scotland, as there is no significant additional cost associated with the combination product compared with its individual components. One trial indicated that fixed combination of Simbrinza® administered BD had a significantly greater IOP lowering effect compared to either brinzolamide 1% or brimonidine 0.2% alone and displayed a safety profile consistent with its individual components. Another trial noted Simbrinza® to be non-inferior to separate administration of brimonidine and brinzolamide less than 10 min apart to prevent wash out. 1 Formulary application: Opthamology department: Consultant submitting application: Mr Lynval Jones (Consultant Ophthalmologist, Glaucoma) Clinical Director supporting application: Gareth Rowland (Clinical Director of Specialised Surgery) Mr Jones has requested for Simbrinza® to be considered for inclusion in the North Staffordshire Joint Formulary for the treatment of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension who have not responded to monotherapy.
    [Show full text]
  • View Board, Austin, Texas, As Well As the Ethics Com- Pendent Examiner in the Same Room with the Same Instru- Mittee of Eye Center and Research, Aseer, Saudi Arabia
    Abdelkader and Kaufman Eye and Vision (2016) 3:31 DOI 10.1186/s40662-016-0065-3 RESEARCH Open Access Clinical outcomes of combined versus separate carbachol and brimonidine drops in correcting presbyopia Almamoun Abdelkader1* and Herbert E. Kaufman2 Abstract Background: To test and compare in a masked fashion the efficacy of using a parasympathomimetic drug (3% carbachol) and an alpha-2 agonist (0.2% brimonidine) in both combined and separate forms to create optically beneficial miosis to pharmacologically improve vision in presbyopia. Methods: A prospective, double-masked, randomized, controlled clinical trial was conducted. Ten naturally emmetropic and presbyopic subjects between 42 and 58 years old with uncorrected distance visual acuity of at least 20/20 in both eyes without additional ocular pathology were eligible for inclusion. All subjects received 3% carbachol and 0.2% brimonidine in both combined and separate forms, 3% carbachol alone and 0.2% brimonidine (control) alone in their non-dominant eye in a crossover manner with one week washout between tests. The subjects’ pupil sizes and both near and distance visual acuities will be evaluated pre- and post-treatment at 1, 2, 4, and 8 h, by a masked examiner at the same room illumination. Results: Statistically significant improvement in mean near visual acuity (NVA) was achieved in all subjects who received combined 3% carbachol and 0.2% brimonidine in the same formula compared with those who received separate forms or carbachol alone or brimonidine alone (P < 0.0001). Conclusion: Based on the data, the combined solution demonstrated greater efficacy than the other solutions that were tested.
    [Show full text]
  • Hyperlinked Region IX SOP for MWLCEMS
    2 Region IX 2 0 0 STANDARD OPERATING PROCEDURES/ 1 1 STANDING MEDICAL ORDERS 9 9 McHenry Western Lake County EMS System Healthcare delivery requires structure (people, equipment, education) and process (policies, protocols, procedures) that, when integrated, produce a system (programs, organizations, cultures) that leads to optimal outcomes (patient survival and safety, quality, satisfaction). An effective system of care comprises all of these elements—structure, process, system, and patient outcomes—in a framework of continuous quality improvement (AHA, 2015). These protocols have been developed and approved through a collaborative process involving the Advocate Lutheran General; Greater Elgin Area, McHenry Western Lake County, Northwest Community, Amita Saint Joseph Hospital, and Southern Fox Valley EMS Systems to reduce variation in practice and establish a Region-wide System of care. They shall be used: as the written practice guidelines/pathways of care approved by the EMS Medical Directors (EMS MDs) to be initiated by System EMS personnel for off-line medical control. as the standing medical orders to be used by Emergency Communications Registered Nurses (ECRNs) when providing on-line medical control (OLMC). in medium to large scale multiple patient incidents, given that the usual and customary forms of communication are contraindicated as specified in the Region IX disaster plan. System members are authorized to implement these orders to their scope of practice. OLMC communication shall be established without endangering the patient. Under no circumstances shall emergency prehospital care be delayed while attempting to establish contact with a hospital. In the event that communications cannot be established, EMS personnel shall continue to provide care to the degree authorized by their license, these protocols, drugs/equipment available, and their scope of practice granted by the EMS MD in that System.
    [Show full text]
  • 0Bcore Safety Profile
    Core Safety Profile Active substance: Levobunolol Pharmaceutical form(s)/strength: Eye drops solution/ 0,1%; 0,25%; 0,5%; 0,5% UD P-RMS: CZ/H/PSUR/0006/001 Date of FAR: 26.05.2009 4.2 Posology and method of administration Adults (including the elderly) Country specific posology and method of administration to be included. Children /.../ is not recommended for use in children due to lack of safety and efficacy data. If required, /.../ may be used with other agents to lower intra-ocular pressure. The use of two topical beta-adrenergic blocking agents is not recommended (see section 4.4). Intraocular pressure should be measured approximately four weeks after starting treatment with /.../ as a return to normal ocular pressure can take a few weeks. As with any eye drops, to reduce possible systemic absorption, it is recommended that the lachrymal sac is compressed at the medial canthus (punctual occlusion) for one minute. This should be performed immediately following the instillation of each drop. Transfer from other beta-blocking treatment When another beta blocking agent is being used treatment must be discontinued after a full day of therapy. Start treatment with /.../ the next day with X drop of /.../ topically applied into the conjunctival sac in the affected eye(s). If /.../ is to replace a combination of anti-glaucoma products, only a single product should be removed at a time. Use in renal and hepatic impairment Levobunolol hydrochloride has not been studied in patients with hepatic or renal impairment. Therefore, caution should be used in treating such patients (see section 4.4).
    [Show full text]
  • BETA RECEPTOR BLOCKERS MC Objective
    Jack DeRuiter, Principles of Drug Action 2, Fall 2000 ADRENERGIC RECEPTOR ANTAGONISTS: BETA RECEPTOR BLOCKERS MC Objective: Describe the development of beta antagonists ("beta blockers") from the agonist norepinephrine (NE): HO H NH2 NE Alpha- and Beta-receptor agonist HO OH H H HO CH N 3 H Isoproterenol CH3 Selective beta-receptor agonist HO OH H H HO CH N 3 H Dichloroisoproterenol CH3 Partial beta-receptor agonist/antagonist Cl Cl H H HO CH N 3 Pronethalol H Beta-receptor antagonist, CH 3 low activity and toxic CH3 O N H Propranolol CH3 OH H Potent beta-antagonist No beta-receptor subtype selectivity CH3 CH3 O N H O N H CH CH OH H 3 OH H 3 Metoprolol N Beta-1-receptor H Pindolol O subtype selectivity Partial beta-agonist CH3 No beta-receptor subtype selectivity HO H H N H CH3 HO Labetolol O NH2 Dual alpha- and beta-antagonst 1 Jack DeRuiter, Principles of Drug Action 2, Fall 2000 MC Objective: Based on their structures, would the beta-blockers be expected to be relatively receptor selective? YES. They do not produce significant blockade of alpha- adrenergic receptors (alpha-1 or alpha-2), histamine receptors, muscarinic receptors or dopamine receptors. MC/PC Objective: Identify which beta blockers are classified as "non-selective": · The “non-selective" classification refers to those beta-blockers capable of blocking BOTH beta-1 and beta-2 receptors with equivalent efficacy. These drugs DO NOT have clinically significant affinity for other neurotransmitter receptors (alpha, dopamine, histamine, acetylcholine, etc.). · ALL of these beta-blockers (except satolol) consist of an aryloxypropanolamine side chain linked to an aromatic or “heteroaromatic” ring which is “ortho” substituted.
    [Show full text]
  • Pharmacology of Ophthalmologically Important Drugs James L
    Henry Ford Hospital Medical Journal Volume 13 | Number 2 Article 8 6-1965 Pharmacology Of Ophthalmologically Important Drugs James L. Tucker Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal Part of the Chemicals and Drugs Commons, Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons Recommended Citation Tucker, James L. (1965) "Pharmacology Of Ophthalmologically Important Drugs," Henry Ford Hospital Medical Bulletin : Vol. 13 : No. 2 , 191-222. Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol13/iss2/8 This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health System Scholarly Commons. For more information, please contact [email protected]. Henry Ford Hosp. Med. Bull. Vol. 13, June, 1965 PHARMACOLOGY OF OPHTHALMOLOGICALLY IMPORTANT DRUGS JAMES L. TUCKER, JR., M.D. DRUG THERAPY IN ophthalmology, like many specialties in medicine, encompasses the entire spectrum of pharmacology. This is true for any specialty that routinely involves the care of young and old patients, surgical and non-surgical problems, local eye disease (topical or subconjunctival drug administration), and systemic disease which must be treated in order to "cure" the "local" manifestations which frequently present in the eyes (uveitis, optic neurhis, etc.). Few authors (see bibliography) have attempted an introduction to drug therapy oriented specifically for the ophthalmologist. The new resident in ophthalmology often has a vague concept of the importance of this subject, and with that in mind this paper was prepared.
    [Show full text]
  • Antiglaucoma Compositions Containing Combinations of Alpha-2 Agonists and Beta-Blockers
    ~" ' MM II II II MM II II II Ml II II I II J European Patent Office _ _ _ © Publication number: 0 365 662 B1 Office europeen* des.. brevets , © EUROPEAN PATENT SPECIFICATION © Date of publication of patent specification: 09.03.94 © Int. CI.5: A61 K 31/47 © Application number: 89905874.7 @ Date of filing: 26.04.89 © International application number: PCT/US89/01994 © International publication number: WO 89/10126 (02.11.89 89/26) (54) ANTIGLAUCOMA COMPOSITIONS CONTAINING COMBINATIONS OF ALPHA-2 AGONISTS AND BETA-BLOCKERS. ® Priority: 26.04.88 US 186504 1075-1078 @ Date of publication of application: J. of Cardiovascular Pharmacology, vol. 2, 02.05.90 Bulletin 90/18 suppl. 1, 1980, S. 21-28 © Publication of the grant of the patent: © Proprietor: ALCON LABORATORIES INC 09.03.94 Bulletin 94/10 6201 South Freeway Ft. Worth, TX 76134(US) © Designated Contracting States: AT BE CH DE FR GB IT LI LU NL SE @ Inventor: DE SANTIS, Louis, M. 2316 Wlnton Terrace West © References cited: Fort Worth, TX 761 09(US) US-A- 4 455 317 US-A- 4 515 800 © Representative: Jump, Timothy John Simon et AM A DRUG EVALUATION, 2nd ed., 1973; al "Agent used to treat Glaucoma", pp. 675-686. Venner Shipley & Co. 20 Little Britain GLAUCOMA, vol. 1, no. 1, February 1979; London EC1A 7DH (GB) 00 S.SUGAR, pp. 9-15. CM CO Ophthalmology, vol. 96, no. 1, 1989, p. 3-7 CO m Ophthalmology, vol. 98, no. 7, 1991, p. CO 00 Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]